ReviewBiology of reproduction2023
Maternal serotonin: implications for the use of selective serotonin reuptake inhibitors during gestation†.
Review in Biology of reproduction, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Antidepressant Use During Pregnancy and Birth Outcomes: Analysis From the UK, Norway, and Sweden.Pharmacoepidemiology and drug safety · 2026Article
- Effect of Sertraline on Fetoplacental Growth Parameters and Placental Transporter Gene Expression in Rats.International journal of molecular sciences · 2026Article
- Selective serotonin reuptake inhibitor use during pregnancy and maternal depression-a nationwide birth cohort study on risks to the mother and the newborn.American journal of obstetrics & gynecology MFM · 2026Article
- Metabolomic insights: LC-MS profiling of human placental tissue from SSRI-treated pregnancies.European journal of medical research · 2026Article
- Placental and fetal consequences of maternal selective serotonin reuptake inhibitor use: current evidence and unresolved questions.Frontiers in pharmacology · 2026Review
- Uterotropic response to the antidepressant fluoxetine (Prozac) is dependent on a functional serotonin transporter and circulating serotonin.Scientific reports · 2025Article
- Analysis of insertion/deletion variation of litter size in Guizhou black goat.Tropical animal health and production · 2025Article
- Gestational vortioxetine exposure impairs pregnancy outcomes and fetal brain development via modulation of BDNF/Bax-Bcl2/5-HT pathways in rats.Archives of toxicology · 2025Article
- Prenatal treatment with the antidepressant fluoxetine on maternal and neonatal behavior in sheep.Pediatric research · 2025Article
- Sertraline use in pregnancy and placental transfer: A pharmacokinetic prospective cohort study.Pregnancy (Hoboken, N.J.) · 2025Article
- Impact of Chronic Fluoxetine Exposure on Oocyte Development and Reproductive Outcomes in a Mouse Model.International journal of molecular sciences · 2025Article
- Fluoxetine exposure alters behavior and morphology ofmicroPublication biology · 2025Article
- Timing of selective serotonin reuptake inhibitor use and risk for preterm birth and related adverse events: with a consideration of the COVID-19 pandemic period.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2024Article
- The antidepressant fluoxetine (Prozac®) modulates serotonin signaling to alter maternal peripartum calcium homeostasis.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Maternal use of antidepressants has increased throughout the last decades; selective serotonin reuptake inhibitors (SSRI) are the most prescribed antidepressants. Despite the widespread use of SSRI by women during reproductive age and pregnant women, an increasing amount of research warns of possible detrimental effects of maternal use of SSRI during pregnancy including low birthweight/small for gestational age and preterm birth. In this review, we revisited the impact of maternal use of SSRI during pregnancy, its impact on serotonin homeostasis in the maternal and fetal circulation and the placenta, and its impact on pregnancy outcomes-particularly intrauterine growth restriction and preterm birth. Maternal use of SSRI increases maternal and fetal serotonin. The increase in maternal circulating serotonin and serotonin signaling likely promotes vasoconstriction of the uterine and placental vascular beds decreasing blood perfusion to the uterus and consequently to the placenta and fetus with potential impact on placental function and fetal development. Several adverse pregnancy outcomes are similar between women, sheep, and rodents (decreased placental size, decreased birthweight, shorter gestation length/preterm birth, neonatal morbidity, and mortality) highlighting the importance of animal studies to assess the impacts of SSRI. Herein, we address the complex interactions between maternal SSRI use during gestation, circulating serotonin, and the regulation of blood perfusion to the uterus and fetoplacental unit, fetal growth, and pregnancy complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.